Breast Cancer | Specialty

The OncLive Breast Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of breast cancer, including those that are triple negative, hormone receptor positive, and/or HER2 positive. This page features news articles, interviews in written and video format, and podcasts that focus on treatment advances and ongoing research in breast cancer.

Esserman Helps Push Breast Cancer Prevention Beyond Routine Screenings

February 18th 2019

Laura J. Esserman, MD, MBA, a 2018 Giants of Cancer Care® award winner in the Cancer Diagnostics category led the way in designing the I-SPY clinical trials, a groundbreaking effort to match patients with breast cancer to potential therapies based on molecular drivers of disease. She also has advocated for a greater understanding of the biological drivers of breast cancer, rather than relying on mass screening programs, to better analyze early disease.

Novel Agents Spark New Approaches for Triple-Negative Breast Cancer

February 15th 2019

During a recent OncLive Peer Exchange®, a panel of breast cancer experts discussed emerging agents in triple-negative breast cancer, which include an anti–PD-L1 antibody, 2 PARP inhibitors, and a novel antibody–drug conjugate.

Dr. Burris on Molecular Profiling in Breast Cancer

February 12th 2019

Howard "Skip" A. Burris, III, MD, chief medical officer, Sarah Cannon Research Institute, 2019 ASCO president-elect, and a 2014 Giant of Cancer Care® in Drug Development, discusses the impact of molecular profiling in breast cancer.

CDK4/6 Inhibitors Changing Course of Care in HR+/HER2- Breast Cancer

February 9th 2019

Earlier diagnosis and more effective therapeutic options are enabling physicians to deliver better rates of disease control and improved quality of life to patients with hormone receptor–positive, HER2-negative metastatic breast cancer.

Cristofanilli Explains Precision of Liquid Biopsies in Advanced Breast Cancer

February 7th 2019

Massimo Cristofanilli, MD, discusses the clinical utility of liquid biopsies—specifically focusing on circulating tumor cells and cell-free DNA—and highlights ongoing research in the space.

Dr. Yardley on Importance of Tailoring Treatment to Breast Cancer Subtypes

February 7th 2019

Denise Yardley, MD, senior investigator, Sarah Cannon Research Institute, discusses the importance of tailoring treatment approaches to the different subtypes of patients with breast cancer.

Novel Approaches for TNBC Make Waves for Patient Outcomes

February 6th 2019

Komal Jhaveri, MD, discusses the 3 major classes of drugs showing potential in the TNBC pipeline.

Pivotal Findings Lead to Changing Standards of Care in Breast Cancer

February 3rd 2019

Denise A. Yardley, MD, discusses key data presented at the 2018 SABCS and the impact of the SOLAR-1 findings.

Burris Discusses Pivotal Data, Next Steps in Breast Cancer

February 1st 2019

Howard A. “Skip” Burris, MD, highlights some of the exciting updates from the 2018 San Antonio Breast Cancer Symposium and what can be expected in the breast cancer field in the year ahead.

Dr. Graff on Tamoxifen De-Escalation in Breast Cancer

February 1st 2019

Stephanie L. Graff, MD, director of the Breast Program at the Sarah Cannon Cancer Institute of HCA Midwest Health, and associate director of the Breast Cancer Research Program at Sarah Cannon Research Institute, discusses the use of tamoxifen in the treatment of patients with breast cancer.

Dr. Cristofanilli on Using CTC to Stratify Patients With Breast Cancer

January 31st 2019

Massimo Cristofanilli, MD, professor of medicine (hematology and oncology), Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, discusses using circulating tumor cells to risk stratify patients with advanced breast cancer.

HR+ Breast Cancer Studies Explore Escalation, De-Escalation Strategies

January 31st 2019

Stephanie L. Graff, MD, discusses the latest updates on escalation and de-escalation of therapy in patients with HR-positive breast cancer.

Lead Researcher Discusses Durvalumab/Olaparib Combo in Breast Cancer

January 30th 2019

Susan Domcheck, MD, discusses the updated results of the MEDIOLA trial in patients with germline BRCA-mutated metastatic breast cancer and speaks to the next phase of development with the combination.

Dr. Esserman on the Elements of the I-SPY 2 Trial in Breast Cancer

January 30th 2019

Laura J. Esserman, MD, MBA, professor, University of California, San Francisco Helen Diller Comprehensive Cancer Center, 2018 Giant of Cancer Care® for Cancer Diagnostics, discusses the elements of the I-SPY 2 trial in breast cancer.

CDK4/6 Inhibitors, Alpelisib Continue to Show Benefit in HR+/HER2- Breast Cancer

January 30th 2019

Kevin Kalinsky, MD, MS, highlights the recent data with alpelisib and CDK4/6 inhibitors, the toxicity differences between the 3 available CDK4/6 agents, and the next steps for both classes of agents.

Dr. Sparano on Improving Liquid Biopsies in Breast Cancer

January 30th 2019

Joseph A. Sparano, MD, associate director for clinical research, Albert Einstein Cancer Center, Montefiore Medical Center, discusses ways to improve the clinical utility of liquid biopsies in the treatment of patients with breast cancer.

Hamilton Highlights Single-Agent Abemaciclib Data in HR+/HER2- Breast Cancer

January 28th 2019

Erika P. Hamilton, MD, discusses the findings from the phase II nextMONARCH 1 study of abemaciclib in HR-positive, HER2-negative advanced breast cancer.

Extended Adjuvant Therapy in Breast Cancer Requires Individualized Approach

January 26th 2019

Paula Klein, MD, discusses the research surrounding extended adjuvant therapy in early-stage hormone receptor-positive breast cancer.

SABCS 2018 Showcased Practice-Changing Advances in Breast Cancer

January 25th 2019

Stephen C. Malamud, MD, reflects on the intriguing and practice-changing data presented at the 2018 SABCS.

TNBC Pipeline Bursting With Effective Agents

January 24th 2019

Meghna Trivedi, MD, highlights 3 classes of agents that are showing promise in patients with metastatic triple-negative breast cancer.